These guidelines differentiate between advanced SS and advanced MF, placing MOG as a second-line treatment with other antibodies, allogeneic hematopoietic progenitor cell transplantation, or chemotherapy after the failure of classic treatments. This evidence concerns the gene MOG and mycosis fungoides.